Shanmugapriya Reddy, MD
Rheumatology · Riverview, FLNPI 1710039045
Payments from drug & device makers
Across 1,125 payments — averaging $1191.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$372K
- Eli Lilly$265K
- UCB, Inc.$164K
- Amgen$148K
- GSK$123K
- Sanofi$57K
- plus $213K from 30 others
Across 2 payments — averaging $7727.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$15K
What the payments were for
- Consulting fees$127,58826%
- Speaking & faculty fees$282,25259%
- Grants$2400%
- Travel & lodging$48,04610%
- Food & beverage$24,1515%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 181 | $372,045 |
| Eli Lilly | 8 | $264,608 |
| UCB, Inc. | 210 | $163,714 |
| Amgen(2 entities) | 259 | $147,804 |
| GSK | 46 | $122,977 |
| Sanofi | 66 | $56,738 |
| Pfizer | 101 | $49,881 |
| Sanofi US Services Inc. | 5 | $45,870 |
| E.r. Squibb & Sons, L.L.C. | 32 | $39,801 |
| Novartis | 58 | $31,142 |
| Argenx US, Inc. | 7 | $25,784 |
| Johnson & Johnson(2 entities) | 44 | $13,738 |
| Sobi, Inc | 6 | $2,582 |
| Gilead | 1 | $1,300 |
| Genentech USA, Inc. | 18 | $352 |
| Octapharma USA, Inc. | 4 | $345 |
| Janssen Scientific Affairs, LLC | 5 | $338 |
| Medexus Pharma, Inc. | 14 | $256 |
| Boehringer Ingelheim | 7 | $192 |
| Aurinia Pharma U.S., Inc. | 6 | $152 |
| Lilly USA, LLC | 7 | $142 |
| AstraZeneca(2 entities) | 7 | $140 |
| Merck | 6 | $109 |
| Mallinckrodt Hospital Products Inc. | 6 | $103 |
| Radius Health, Inc. | 5 | $97 |
| Sanofi-aventis U.S. LLC | 2 | $94 |
| Pacira Therapeutics, Inc. | 4 | $71 |
| Regeneron Healthcare Solutions, Inc. | 1 | $45 |
| Bristol Myers Squibb | 2 | $41 |
| Zimmer Biomet | 1 | $35 |
| Organon | 1 | $25 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Fresenius Kabi USA, LLC | 1 | $20 |
| Oxford Immunotec USA Inc | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,340,611 in reported general payments places this provider in the 95th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 21 | $583 |
| MethotrexateMethotrexate Sodium | 15 | $267 |
| Prednisone | 13 | $148 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Riverview
- Martha Hernandez IllasFort Lauderdale$25M
- Carlos SesinMiami Beach$19M
- Guillermo ValenzuelaPlantation$14.2M
- Marimer Rensoli VelazquezMiami$12.2M
- Robert LevinClearwater$11M
- Jigar ShahMargate$5.6M
- Michael BubbGainesville$3.3M
- Vipul JoshiBrandon$3.1M
- Alvin WellsDestin$2.9M
- Benidecto FernandezHialeah$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.